|

Drug-Drug Interaction Study of ABP-671 in Gout Patients

RECRUITINGPhase 1Sponsored by Atom Therapeutics Co., Ltd
Actively Recruiting
PhasePhase 1
SponsorAtom Therapeutics Co., Ltd
Started2026-01-23
Est. completion2026-07-31
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07367971

Summary

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adults 18-75 years with clinical diagnosis of gout.
* Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
* Cohort N: Normal renal function.
* Cohort R: Moderate renal impairment.

Exclusion Criteria:

* Clinically significant hepatic impairment.
* History of Allopurinol hypersensitivity.
* Pregnancy or breastfeeding.

Conditions4

ArthritisDDI (Drug-Drug Interaction)GoutGout Chronic

Interventions1

ABP-671 plus allopurinol

Locations1 site

Wakefield Clinical Research
Cary, North Carolina, 27560
Xiaohuan Li, MD

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.